MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms.
A drug class blocking a cancer-protective protein shows unexpected promise specifically in myelofibrosis, opening a new disease-focused strategy after years of AML-focused research.
This comprehensive Leukemia review synthesizes decades of MDM2-p53 biology and translates it through successive clinical trial generations, identifying myelofibrosis — not AML — as the disease where MDM2 inhibition shows most disease-modifying promise. Emerging degraders and rational combinations (JAK inhibitors, BCL-2 antagonists, interferons) are highlighted as next-generation strategies.
What the study was
- Study design
- Narrative review
- Population
- AML and MPN patients in clinical trials
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
High-impact Leukemia journal; authoritative synthesis of MDM2 inhibitor clinical data in MPN including emerging degrader class; useful downstream for treatment landscape analysis.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.